Licochalcone BCAS# 58749-23-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 58749-23-8 | SDF | Download SDF |
| PubChem ID | 5318999 | Appearance | White powder |
| Formula | C16H14O5 | M.Wt | 286.28 |
| Type of Compound | Chalcones | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (E)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one | ||
| SMILES | COC1=C(C=CC(=C1O)O)C=CC(=O)C2=CC=C(C=C2)O | ||
| Standard InChIKey | DRDRYGIIYOPBBZ-XBXARRHUSA-N | ||
| Standard InChI | InChI=1S/C16H14O5/c1-21-16-11(5-9-14(19)15(16)20)4-8-13(18)10-2-6-12(17)7-3-10/h2-9,17,19-20H,1H3/b8-4+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Licochalcone B has antitumor, antimetastatic, cardioprotective, antioxidant, antiapoptotic, and anti-inflammatory effects, it can significantly inhibit LPS-induced phosphorylation at serine 276 and transcriptional activation of NF-KB. Licochalcone B can protect the liver from carbon tetrachloride (CCl4)-induced injury, the protection may be due to inhibition of p38 and NFκB signaling, which subsequently reduces inflammation in the liver. |
| Targets | CDK | PARP | Bcl-2/Bax | p38MAPK | Caspase | MMP(e.g.TIMP) | NF-kB | p65 | AP-1 | IkB | TNF-α | PKA | NO | ROS | IL Receptor | IKK |
| In vitro | Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis.[Pubmed: 24384411]Food Chem Toxicol. 2014 Mar;65:242-51.To examine the mechanisms by which Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model. Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway.[Pubmed: 19291859]Int Immunopharmacol. 2009 Apr;9(4):499-507.Licorice root has been used as a traditional medicine for the treatment of gastric ulcer, bronchial asthma and inflammation. Licochalcone A is a major component of Xinjiang licorice, Glycyrrhiza inflata. |
| In vivo | (E)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one, a novel licochalcone B derivative compound, suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice.[Pubmed: 25451593]Chem Biol Interact. 2014 Oct 29;224C:142-148.Activated macrophages mediate inflammation, as they release nitric oxide and pro-inflammatory cytokines in various inflammatory diseases. Suppressing macrophage activation may alleviate inflammatory processes. Cardioprotection against ischemia/reperfusion by licochalcone B in isolated rat hearts.[Pubmed: 25215172]Oxid Med Cell Longev. 2014;2014:134862.The generation of reactive oxygen species (ROS) is a major cause of heart injury induced by ischemia-reperfusion. The left ventricular developed pressure (LVDP) and the maximum up/down rate of left ventricular pressure (±dp/dt(max)) were documented by a physiological recorder. |
| Kinase Assay | Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity.[Pubmed: 25099010]Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):527-33.This study investigated the mechanisms by which Licochalcone B (LCB) inhibits the adhesion,invasion and metastasis of human malignant bladder cancer T24 cells. |
| Animal Research | Hepatoprotective effects of licochalcone B on carbon tetrachloride-induced liver toxicity in mice.[Pubmed: 27746874 ]Iran J Basic Med Sci. 2016 Aug;19(8):910-5.The objective of this study was to investigate the hepatoprotective effect of Licochalcone B (LCB) in a mice model of carbon tetrachloride (CCl4)-induced liver toxicity. |
Licochalcone B Dilution Calculator
Licochalcone B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | 69.8617 mL | 87.3271 mL |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | 13.9723 mL | 17.4654 mL |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL | 6.9862 mL | 8.7327 mL |
| 50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.3972 mL | 1.7465 mL |
| 100 mM | 0.0349 mL | 0.1747 mL | 0.3493 mL | 0.6986 mL | 0.8733 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Licochalcone A
Catalog No.:BCN6332
CAS No.:58749-22-7
- H-D-Ser-OMe.HCl
Catalog No.:BCC3098
CAS No.:5874-57-7
- 16-Oxoprometaphanine
Catalog No.:BCN5797
CAS No.:58738-31-1
- H-D-Cha-OH
Catalog No.:BCC2662
CAS No.:58717-02-5
- Dihydrokavain
Catalog No.:BCN2677
CAS No.:587-63-3
- 3,4-Dichloro-Phe-OH
Catalog No.:BCC2636
CAS No.:587-56-4
- 2-C-Methyl-D-erythritol
Catalog No.:BCC8570
CAS No.:58698-37-6
- Boc-Cys(Acm)-ONp
Catalog No.:BCC3375
CAS No.:58651-76-6
- PH-797804
Catalog No.:BCC3672
CAS No.:586379-66-0
- Boc-ON
Catalog No.:BCC2797
CAS No.:58632-95-4
- H- ß-HoGlu-OH.HCl
Catalog No.:BCC3232
CAS No.:58610-41-6
- m-Anisic acid
Catalog No.:BCC9015
CAS No.:586-38-9
- Proparacaine HCl
Catalog No.:BCC5073
CAS No.:5875-06-9
- Meranzin hydrate
Catalog No.:BCN5798
CAS No.:5875-49-0
- Haplopine
Catalog No.:BCN3921
CAS No.:5876-17-5
- Pinostilbenoside
Catalog No.:BCN5799
CAS No.:58762-96-2
- Alpha-Belladonnine
Catalog No.:BCN1894
CAS No.:5878-33-1
- ZCL278
Catalog No.:BCC3665
CAS No.:587841-73-4
- C7280948
Catalog No.:BCC6443
CAS No.:587850-67-7
- ABT 724 trihydrochloride
Catalog No.:BCC7293
CAS No.:587870-77-7
- KU 55933
Catalog No.:BCC2475
CAS No.:587871-26-9
- Benzalazine
Catalog No.:BCC8843
CAS No.:588-68-1
- Toosendanin
Catalog No.:BCN1007
CAS No.:58812-37-6
- SB 297006
Catalog No.:BCC6129
CAS No.:58816-69-6
Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway.[Pubmed:19291859]
Int Immunopharmacol. 2009 Apr;9(4):499-507.
Licorice root has been used as a traditional medicine for the treatment of gastric ulcer, bronchial asthma and inflammation. Licochalcone A is a major component of Xinjiang licorice, Glycyrrhiza inflata. Previously we showed that Licochalcone A significantly inhibited LPS-induced NF-kappaB transcriptional activation by abrogating the phosphorylation of NF-kappaB p65 at serine 276. Glycyrrhiza inflata contains not only Licochalcone A but also Licochalcone B, Licochalcone C, Licochalcone D, Echinatin and Isoliquiritigenin, harboring the common structure of chalcones. No chalcones had any effect on LPS-induced IkappaB degradation, nuclear translocation and DNA binding activity of NF-kappaB p65; however, we observed that Licochalcone B and Licochalcone D significantly inhibited LPS-induced phosphorylation at serine 276 and transcriptional activation of NF-kappaB, the same as Licochalcone A. Interestingly, we also found that Licochalcone A, Licochalcone B and Licochalcone D effectively inhibited LPS-induced activation of PKA, which is required for the phosphorylation of NF-kappaB p65 at serine 276. Consequently, Licochalcone B and Licochalcone D significantly reduced the LPS-induced production of NO, TNFalpha and MCP-1. On the other hand, Licochalcone C, Echinatin and Isoliquitigenin failed to inhibit LPS-induced NF-kappaB activation. These findings suggest that the anti-inflammatory effect of Glycyrrhiza inflata is ascribable to the potent inhibition of NF-kappaB by Licochalcone A, Licochalcone B and Licochalcone D.
Cardioprotection against ischemia/reperfusion by licochalcone B in isolated rat hearts.[Pubmed:25215172]
Oxid Med Cell Longev. 2014;2014:134862.
The generation of reactive oxygen species (ROS) is a major cause of heart injury induced by ischemia-reperfusion. The left ventricular developed pressure (LVDP) and the maximum up/down rate of left ventricular pressure (+/-dp/dt(max)) were documented by a physiological recorder. Myocardial infarct size was estimated macroscopically using 2,3,5-triphenyltetrazolium chloride staining. Coronary effluent was analyzed for lactate dehydrogenase (LDH) and creatine kinase (CK) release to assess the degree of cardiac injury. The levels of C-reactive protein (CRP), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) were analyzed to determine the inflammation status of the myocardial tissue. Cardiomyocyte apoptosis analysis was performed using the In Situ Cell Death Detection Kit, POD. Accordingly, Licochalcone B pretreatment improved the heart rate (HR), increased LVDP, and decreased CK and LDH levels in coronary flow. SOD level and GSH/GSSG ratio increased, whereas the levels of MDA, TNF-alpha, and CRP and activities of IL-8 and IL-6 decreased in Licochalcone B-treated groups. The infarct size and cell apoptosis in hearts from Licochalcone B-treated group were lower than those in hearts from the I/R control group. Therefore, the cardioprotective effects of Licochalcone B may be attributed to its antioxidant, antiapoptotic, and anti-inflammatory activities.
Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis.[Pubmed:24384411]
Food Chem Toxicol. 2014 Mar;65:242-51.
To examine the mechanisms by which Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model. Exposure of T24 or EJ cells to LCB significantly inhibited cell lines proliferation in a concentration-dependent and time-dependent manner, and resulted in S phase arrest in T24 or EJ cells, respectively. LCB treatment decreased the expression of cyclin A, cyclin-dependent kinase (CDK1 and CDK2) mRNA, cell division cycle 25 (Cdc25A and Cdc25B) protein. In addition, LCB treatment down-regulated Bcl-2 and survivin expression, enhanced Bax expression, activated caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) protein. Consistently, the tumorigenicity of LCB-treated MB49 cells was limited significantly by using the colony formation assay in vitro and the MB49 tumor model performed in C57BL/6 mice in vivo. These findings provide support for the use of LCB in chemoprevention and bladder cancer therapy.
(E)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one, a novel licochalcone B derivative compound, suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice.[Pubmed:25451593]
Chem Biol Interact. 2014 Dec 5;224:142-8.
Activated macrophages mediate inflammation, as they release nitric oxide and pro-inflammatory cytokines in various inflammatory diseases. Suppressing macrophage activation may alleviate inflammatory processes. Here, we report that (E)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (DDP), a novel Licochalcone B derivative compound, inhibits inflammatory reactions in macrophages and protects mice from endotoxin shock. In vitro experiments showed that DDP suppressed the generation of nitric oxide and pro-inflammatory cytokines by suppressing the activation of nuclear factor-kappaB and activator protein-1 and simultaneously inhibited its upstream inflammatory signaling cascades in lipopolysaccharide in RAW264.7 cells. In an animal model, DDP protected BALB/c mice from lipopolysaccharide-induced endotoxin shock, possibly through inhibition of the production of inflammatory cytokines. DDP inhibited the production of inflammatory mediators and may be a potential target for treatment of various inflammatory diseases.
Hepatoprotective effects of licochalcone B on carbon tetrachloride-induced liver toxicity in mice.[Pubmed:27746874]
Iran J Basic Med Sci. 2016 Aug;19(8):910-915.
OBJECTIVES: The objective of this study was to investigate the hepatoprotective effect of Licochalcone B (LCB) in a mice model of carbon tetrachloride (CCl4)-induced liver toxicity. MATERIALS AND METHODS: Hepatotoxicity was induced in mice by a single subcutaneous injection (SC) of CCl4. The LCB was administered orally once a day for seven days (PO) as pretreatment at three doses of 1, 5, and 25 mg/kg/day. The levels of superoxide dismutase (SOD), malondialdehyde (MDA), glutathione (GSH), glutathione disulfide (GSSG), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were analyzed by ELISA. The protein expression degrees of p38 mitogen activated protein kinases (p38) and nuclear factor-k-gene binding (NF-kappaB) were assayed by western blotting. RESULTS: CCl4-induced hepatotoxicity was manifested by an increase in the levels of ALT, AST, MDA, IL-6, CRP, and TNF-a, and a decrease in the SOD level and GSH/GSSG ratio in the serum. The histopathological examination of the liver sections revealed necrosis and inflammatory reactions. Pretreatment with LCB decreased the levels of ALT, AST, MDA, GSSG, IL-6, CRP, TNF-a, and the protein expression of p38 and NF-kappaB, increased the level of SOD and GSH, and normalized the hepatic histo-architecture. CONCLUSION: LCB protected the liver from CCl4-induced injury. Protection may be due to inhibition of p38 and NFkappaB signaling, which subsequently reduced inflammation in the liver.
Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-small ka, CyrillicB activity.[Pubmed:25099010]
Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):527-33.
This study investigated the mechanisms by which Licochalcone B (LCB) inhibits the adhesion,invasion and metastasis of human malignant bladder cancer T24 cells. Cell viability was evaluated using a sulforhodamine B (SRB) assay. Cell migration and invasion ability were conducted using wound-healing assay and matrigel transwell invasion assay. The activities of matrix metalloproteinases (MMP)-2 and MMP-9 were measured by gelatin zymography protease assays. The expression in protein level of NF-kappaBP65 and AP-1 was determined using the ELISA method; the protein levels of MMP-9, NF-kappaBP65, IkappaBalpha and P-IkappaBalpha were detected by Western blot. The expression in mRNA level of MMP-9 was assessed using quantitative real-time polymerase chain reaction (PCR) and reverse transcription PCR. The results indicated that LCB attenuated T24 cell migration, adhesion and invasion in a concentration-dependent manner. LCB treatment down-regulated the mRNA expression, protein expression and activity of MMP-9 but had no effect on MMP-2. In addition, LCB treatment decreased the protein level of NF-small ka, CyrillicBP65 and nuclear translocation of NF-small ka, CyrillicB. These findings suggested that LCB attenuated migration of bladder cancer T24 cells and adhesion and invasion accompanied with down-regulated protein expression of MMP-9 and the nuclear translocation of NF-small ka, CyrillicB. Our results provide support that LCB may be a potent adjuvant therapeutic agent in the prevention and therapy of bladder cancer.
